Hallucinogen persisting perception disorder: what do we know after 50 years?
John H. Halpern, Harrison G. Pope
Drug and Alcohol Dependence March 1, 2003 DOI: 10.1016/s0376-8716(02)00306-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Peer reviewed |
|---|---|
| Key findings | The authors conclude that HPPD appears to be a genuine but uncommon disorder that can persist for months or years and cause substantial morbidity, reported most commonly after illicit LSD use and less commonly with LSD given in research or treatment settings or with other hallucinogens. They argue that current knowledge is severely limited: 'flashbacks' is defined inconsistently, most studies cannot be judged against DSM-IV criteria, and risk factors, mechanisms, and treatment remain uncertain. |
Abstract
'Flashbacks' following use of hallucinogenic drugs have been reported for decades; they are recognized in DSM-IV as 'Hallucinogen Persisting Perception Disorder (Flashbacks)', or HPPD. We located and analyzed 20 quantitative studies between 1955 and 2001 examining this phenomenon. However, many of these studies were performed before operational criteria for HPPD were published in DSM-III-R, so they are difficult to interpret in the light of current diagnostic criteria. Overall, current knowledge of HPPD remains very limited. In particular (1) the term 'flashbacks' is defined in so many ways that it is essentially valueless; (2) most studies provide too little information to judge how many cases could meet DSM-IV criteria for HPPD; and consequently (3) information about risk factors for HPPD, possible etiologic mechanisms, and potential treatment modalities must be interpreted with great caution. At present, HPPD appears to be a genuine but uncommon disorder, sometimes persisting for months or years after hallucinogen use and causing substantial morbidity. It is reported most commonly after illicit LSD use, but less commonly with LSD administered in research or treatment settings, or with use of other types of hallucinogens. There are case reports, but no randomized controlled trials, of successful treatment with neuroleptics, anticonvulsants, benzodiazepines, and clonidine. Although it may be difficult to collect large samples of HPPD cases, further studies are critically needed to augment the meager data presently available regarding the prevalence, etiology, and treatment of HPPD.
Citations in the library
Cited by 115
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
- Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies Journal of Psychopharmacology September 20, 2010
- Constructing drug effects: A history of set and setting Drug Science, Policy and Law 2017
and 110 more in the library
Cites 25
- ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE The Journal of Nervous and Mental Disease October 1, 1984
- The Therapeutic Value of Lysergic Acid Diethylamide in Mental Illness Journal of Mental Science April 1, 1954
- Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) The British Journal of Psychiatry September 1, 1994
- Visual Phenomenology of the LSD Flashback Archives of General Psychiatry August 1, 1983
- A Single Dose of Lysergic Acid Diethylamide Influences Gene Expression Patterns within the Mammalian Brain Neuropsychopharmacology May 1, 2002
and 20 more in the library